TREATMENT OF URINARY INCONTINENCE BY USING MATRIX ALLOGRAFTS HUMAN DERMIS HYDRATED FLEX HD. INITIAL STUDY IN MEXICO

Hypothesis / aims of study
The treatment of urinary incontinence (SUI) discloses advantages and benefits with the new technique with the use of biologic grafts applied shutter and tension free as this method has good results and fewer complications, because no graft rejections or etrución.

Study design, materials and methods
A prospective observational and descriptive study. Clinical records of patients with SUI treated with "FLEX HD" from January to August 2013 in whom allograft acellular human dermis hydrated matrix "Flex HD" Ethicon Johnson & Johnson was used were reviewed. In which assessed age, pregnancies, diagnosis, body mass index, anesthesia, operative bleeding, operative time, complications, hospital stay, assessment of continence. Percentages, averages, and measures of central tendency were used.

Results
3 patients 39 to 74 years (48 years average age) were studied. Gestaciones promedio, 3. Were diagnosed with SUI 1, 2 with SUI and cystocele 1 with recurrent SUI. In 100% epidural block was applied. Mean operative time of 24 min. Mean operative bleeding of 30 ml.

Interpretation of results
urinary retention, 0 (0%); Ecchymosis 1; drilling urethra, 0; hospital stay, 1 day. Track 7 and 30 days, urinary continence 100%, 3 months, continence 100%, at 6 and 12 months, 99.07% of urinary continence. Currently continence is 99.07%.

Concluding message
The use of acellular dermal allografts reduces morbidity, operative time, hospital stay, disability, and allows the faster patient rejoin their activities and improve their quality of life without complications etrucción or rejection without further surgery compared with the gold standard for treatment of SUI. In experienced hands surgical time was 12 minutes.

Disclosures
Funding: this research received no specific grant from any funding agency in the public, commercial or not for profit sectors. Clinical Trial: No Subjects: HUMAN Ethics not Req’d: because this is an approval product. Helsinki: Yes Informed Consent: Yes.